Table 2.
MicroRNAs (miRNAs) targeting breast cancer stem cells (BCSCs).
| miRNA | Target | Result on BCSCs | References |
|---|---|---|---|
| miR-7 | KLF4 | -Reduces stemness phenotypes -Inhibits pluripotent potential of stem cells |
(22) |
| miR-9 | Notch signaling | Reduces metastasis | (23) |
| miR-16 | WIP1 | -Reduces self-renewal -Increases sensitivity to doxorubicin (Dox) |
(24) |
| miR-23b | MARCKS | -Inhibiting cell cycle -Inhibiting motility |
(25) |
| miR-29b | -SPIN1 -Wnt/β-catenin and Akt signal pathways -VEGFA -PDGFA/B/C -MMP2/9, ITGA6, -ITGB1, TGFβ2/3 |
-Inhibits self-renewal and growth -Inhibits invasion and metastasis |
(26) |
| miR-30a | Protein AVEN | -Inhibits the growth -Induces apoptosis |
(27) |
| miR-30e | -Ubc9 -ITGB3 |
-Inhibits self-renewal -Induces apoptosis |
(28) |
| miR-34 family (miR-34a and miR-34c) | -Notch signaling -Notch4 |
-Reduces cancer stem cell phenotypes -Suppresses EMT -Suppresses metastasis -Increases sensitivity to Dox and paclitaxel |
(23, 29, 30) |
| miR-93 | Sox4 | -Reduces stemness phenotypes -Promotes differentiation -Inhibits pluripotent potential of stem cells |
(31) |
| miR-126/miR-206/miR-335 | -Sox4 -Tenascin C |
-Reduces stemness phenotypes and proliferation -Inhibits metastasis and migration |
(32) |
| miR-128 | -Nanog -Snail |
-Reduces stemness phenotypes -Inhibits pluripotent potential of stem cells |
(33, 34) |
| miR-140 | -Sox9 -ALDH1 |
-Reduces stemness phenotypes -Inhibits pluripotent potential of stem cells |
(35) |
| miR-148 | -BMI1 -ABCC5 |
-Inhibits progression -Induces apoptosis -Increases sensitivity to Dox |
(33, 34) |
| miR-153 | HIF1α | Inhibits angiogenesis | (36) |
| miR-200 family (miR-200a, miR-200b, and miR-200c) | -BMI1 -Suz12 -Notch pathway components, Jagged1, Maml2/3 -ZEB1/2 |
-Suppresses colony formation -Suppresses tumor formation -Suppresses invasion -Suppresses EMT |
(37–39) |
| miR-600 | -SCD1 enzyme -Wnt/β-catenin pathways |
Promotes differentiation | (40) |
| miR-708 | Neuronatin ERK/FAK pathway | Inhibits migration and metastasis | (41) |
| let-7 | -H-RAS -MYC -HMGA2 -IL-6 -ERα |
-Inhibits self-renewal -Inhibits pluripotent potential of stem cells |
(42, 43) |
KLF4, Kruppel-like factor 4; WIP1, wild-type p53-induced phosphatase 1; MARCKS, myristoylated alanine rich protein kinase C substrate; SPIN1, Spindlin 1; VEGFA, vascular endothelial growth factor A; PDGFA/B/C, platelet-derived growth factor A/B/C; MMP2/9, matrix metalloproteinases 2/9; ITGA6, integrin subunit alpha 6; ITGB1, integrin subunit beta 1; TGFβ2/3, transforming growth factor beta 2/3; Protein AVEN, apoptosis and caspase activation inhibitor; Ubc9, hypothetical protein; ITGB3, integrin subunit beta 3; EMT, epithelial–mesenchymal transition; ALDH1, aldehyde dehydrogenase 1; BMI1, B lymphoma Mo-MLV insertion region 1 homolog, a member of the polycomb repression complex 1 family; ABCC5, multidrug resistance-associated protein 5; HIF1α, hypoxia-inducible factor 1α; Suz12, polycomb repressive complex 2 subunit; Maml2/3, mastermind-like Notch coactivators 2/3; ZEB1/2, zinc finger E-box binding homeobox 1; SCD1, stearoyl-CoA desaturase-1; HMGA2, high-mobility group AT-hook 2; IL-6, interleukin 6; ERα, estrogen receptor α.